新型冠状病毒肺炎治疗中的药物不良反应与防治  

Prevention and Treatment of Adverse Drug Reactions in COVID-19

作　　者：侯静静 龚慧[1,2,3] 赵翊畅 徐萍 张毕奎[1,2,3] 颜苗 HOU Jingjing;GONG Hui;ZHAO Yichang;XU Ping;ZHANG Bikui;YAN Miao(Department of Pharmacy,the Second Xiangyfa Hospital of Central South University,Changsha 410011,China;Institute of Clinical Pharmacy,Central South University,Changsha 410011,China;Toxicology Counseling Center of Hunan Province,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院药学部,湖南长沙410011 [2]中南大学临床药学研究所,湖南长沙410011 [3]湖南省毒物咨询中心,湖南长沙410011

出　　处：《药学进展》2020年第2期153-158,共6页Progress in Pharmaceutical Sciences

摘　　要：围绕《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》中的治疗试用药物,包括抗病毒药物、糖皮质激素和中药,从各药的作用机制、药物相互作用、药物不良反应等方面,综述新型冠状病毒肺炎(COVID-19)治疗中可能出现的不良反应及防治策略,为临床治疗方案的合理选择提供参考。Based on the medication regimens recommended by Diagnosis and Treatment Scheme for COVID-19(Trial Version 6.0), including antiviral drugs, corticosteroids and traditional Chinese medicines, this article reviews the possible adverse reactions and their prevention and treatment strategy during the treatment of COVID-19 in terms of the mechanisms of action, drug interactions and adverse drug reactions, aiming to provide reference for the selection of reasonable therapeutic regimens.

关 键 词：COVID-19 抗病毒药物 药物不良反应 防治 磷酸氯喹 

分 类 号：R563.1[医药卫生—呼吸系统] R978.7[医药卫生—内科学]